Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIA Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma.

Next Previous
Search
Trial Profile

A Phase IIA Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temozolomide (Primary) ; Carmustine; Cytarabine; Dexamethasone; Etoposide; Rituximab
  • Indications B-cell lymphoma; CNS cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DRBEAT

    • Most Recent Events

    • 23 Oct 2018 Status changed from recruiting to discontinued due to poor enrollement.
    • 05 Apr 2016 Planned End Date changed from 1 Dec 2013 to 1 Dec 2019 as per ClinicalTrials.gov record.
    • 05 Apr 2016 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2018 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top